治疗性凝血因子VIII浓缩物中血管性血友病因子抗原多聚体

Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.

作者信息

Vukovich T C

出版信息

Folia Haematol Int Mag Klin Morphol Blutforsch. 1986;113(6):831-40.

Abstract

By crossed immunoelectrophoresis (XIEP), the pattern of von Willebrand factor antigen (vWF:Ag) was investigated in six commercially available factor VIII (F VIII) concentrates and in normal human plasma. At least 5 subpopulations of vWF:Ag were recognized by XIEP in the therapeutic F VIII concentrates and in normal plasma. F VIII preparations high in ristocetin cofactor activity (vWF:RICof) and low in the ratio of vWF:Ag to vWF:RiCof were found to be similar in the multimeric structure of vWF:Ag to normal plasma. However, F VIII concentrates low in activity of vWF:RiCof and high in the ratio of vWF:Ag to vWF:RiCof were found to be deficient in the slowly migrating, high molecular weight multimers of vWF:Ag present in normal plasma.

摘要

通过交叉免疫电泳（XIEP），研究了六种市售凝血因子VIII（F VIII）浓缩物和正常人血浆中血管性血友病因子抗原（vWF:Ag）的模式。XIEP在治疗性F VIII浓缩物和正常血浆中识别出至少5种vWF:Ag亚群。发现瑞斯托霉素辅因子活性（vWF:RICof）高且vWF:Ag与vWF:RiCof比率低的F VIII制剂在vWF:Ag的多聚体结构上与正常血浆相似。然而，发现vWF:RiCof活性低且vWF:Ag与vWF:RiCof比率高的F VIII浓缩物缺乏正常血浆中存在的迁移缓慢的高分子量vWF:Ag多聚体。

相似文献

1

Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.

Folia Haematol Int Mag Klin Morphol Blutforsch. 1986;113(6):831-40.

2

Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.

Semin Thromb Hemost. 2006 Sep;32(6):626-35. doi: 10.1055/s-2006-949668.

3

Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.

Thromb Haemost. 1988 Jun 16;59(3):485-90.

4

Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.

Semin Thromb Hemost. 2002 Apr;28(2):111-32. doi: 10.1055/s-2002-27814.

5

In vitro characterization of various factor VIII concentrates.

Arzneimittelforschung. 1987 Jul;37(7):753-6.

6

Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.

Semin Thromb Hemost. 2002 Apr;28(2):139-48. doi: 10.1055/s-2002-27816.

7

Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.

Acta Haematol. 2009;121(2-3):128-38. doi: 10.1159/000214853. Epub 2009 Jun 8.

8

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Thromb Haemost. 2007 Jun;97(6):922-30.

9

Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.

Semin Thromb Hemost. 2002 Apr;28(2):149-60. doi: 10.1055/s-2002-27817.

10

A critical evaluation of the available methods for the determination of factor VIII von Willebrand.

Folia Haematol Int Mag Klin Morphol Blutforsch. 1986;113(5):670-84.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。